# Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

> **NCT04220996** · PHASE4 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 100 (actual)

## Conditions studied

- MDD
- Anxiety Disorders

## Interventions

- **DRUG:** Vortioxetine

## Key facts

- **NCT ID:** NCT04220996
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-27
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220996, "Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04220996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*